Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kinnate Biopharma (KNTE)
NASDAQ:KNTE
Holding KNTE?
Track your performance easily
KNTE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.04 - $7.19
Previous Close$2.65
Volume2.81M
Average Volume (3M)415.12K
Market Cap
$125.15M
Enterprise Value-$25.71M
Total Cash (Recent Filing)$154.03M
Total Debt (Recent Filing)$3.17M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
May 09, 2024EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.42
Shares Outstanding47,225,312
10 Day Avg. Volume749,176
30 Day Avg. Volume415,115
Standard Deviation0.31
R-Squared0.04
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.79
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.30
Forecast
1Y Price Target
$2.00Price Target Upside-24.53% Downside
Rating ConsensusHold
Number of Analyst Covering2
Kinnate Biopharma News
PremiumCompany Announcements
Kinnate Biopharma’s Strategic Shift and Corporate Evolution
PremiumCompany Announcements
Kinnate Biopharma Strikes Major Deal on Drug Rights
Ownership Overview
0.14% Insiders
5.82% Mutual Funds
69.31% Other Institutional Investors
24.73% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KNTE FAQ
What was Kinnate Biopharma’s price range in the past 12 months?
Kinnate Biopharma lowest stock price was $1.04 and its highest was $7.18 in the past 12 months.
What is Kinnate Biopharma’s market cap?
Currently, no data Available
When is Kinnate Biopharma’s upcoming earnings report date?
Kinnate Biopharma’s upcoming earnings report date is May 09, 2024 which is 134 days ago.
How were Kinnate Biopharma’s earnings last quarter?
Kinnate Biopharma released its earnings results on Mar 25, 2024. The company reported -$0.362 earnings per share for the quarter, beating the consensus estimate of -$0.425 by $0.063.
Is Kinnate Biopharma overvalued?
According to Wall Street analysts Kinnate Biopharma’s price is currently Overvalued.
Does Kinnate Biopharma pay dividends?
Kinnate Biopharma does not currently pay dividends.
What is Kinnate Biopharma’s EPS estimate?
Kinnate Biopharma’s EPS estimate is -$0.29.
How many shares outstanding does Kinnate Biopharma have?
Kinnate Biopharma has 47,225,000 shares outstanding.
What happened to Kinnate Biopharma’s price movement after its last earnings report?
Kinnate Biopharma reported an EPS of -$0.362 in its last earnings report, beating expectations of -$0.425. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kinnate Biopharma?
Among the largest hedge funds holding Kinnate Biopharma’s share is Viking Global Investors LP. It holds Kinnate Biopharma’s shares valued at 4M.
---
Kinnate Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (-24.53% Downside)
$2.00 (-24.53% Downside)
Blogger Sentiment
Neutral
KNTE Sentiment 50%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-58.86%
Trailing 12-Months
Asset Growth
-37.74%
Trailing 12-Months
Company Description
Kinnate Biopharma
Kinnate Biopharma Inc a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The company's product candidate is KIN002787, which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor it is developing for the treatment of patients with lung cancer, melanoma and other solid tumors. Its KIN003 program is evaluating Fibroblast Growth Factor Receptors (FGFR) inhibitor candidates for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining.
---
KNTE Stock 12 Month Forecast
Average Price Target
$2.00
▼(-24.53% Downside)
Technical Analysis
RAPT Therapeutics
―
G1 Therapeutics
―
Crispr Therapeutics AG
―
Oncternal Therapeutics
―
Best Analysts Covering KNTE
1 Year
1 Year Success Rate
2/17 ratings generated profit
1 Year Average Return
-37.03%
reiterated a buy rating 11 months ago
Copying Andrew Berens's trades and holding each position for 1 Year would result in 11.76% of your transactions generating a profit, with an average return of -37.03% per trade.
---